IGC Pharma (AMEX:IGC) reported quarterly losses of $(0.01) per share which beat the analyst consensus estimate of $(0.02) by 50 percent. This is a 75 percent increase over losses of $(0.04) per share from the same period last year. The company reported quarterly sales of $330.000 thousand which beat the analyst consensus estimate of $305.000 thousand by 8.20 percent. This is a 11.86 percent increase over sales of $295.000 thousand the same period last year.